(Q43611862)

25 November 2017

Genetic characteristics of HIV-1 subtype C envelopes inducing cross-neutralizing antibodies (English)

1 reference

25 November 2017

1 reference

Penny L Moore

2

0 references

Elin S Gray

object named as

Elin S Gray

6

0 references

Clive M. Gray

object named as

Clive Gray

8

0 references

Lynn Morris

9

object named as

Lynn Morris

1 reference

25 November 2017

10

Carolyn Williamson

1 reference

25 November 2017

7

Haynes W Sheppard

1 reference

25 November 2017

1

Cecilia Rademeyer

1 reference

25 November 2017

5

Isaac A Choge

1 reference

25 November 2017

Natasha Taylor

3

1 reference

25 November 2017

Darren P Martin

4

1 reference

25 November 2017

HIVNET 028 study team

11

1 reference

25 November 2017

HIVNET 028 study team

12

1 reference

25 November 2017

language of work or name

English

0 references

publication date

16 July 2007

1 reference

25 November 2017

1 reference

25 November 2017

368

1 reference

25 November 2017

1

1 reference

25 November 2017

172-181

1 reference

Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection

25 November 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.06.013

Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.06.013

Regional clustering of shared neutralization determinants on primary isolates of clade C human immunodeficiency virus type 1 from South Africa

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.06.013

Envelope-constrained neutralization-sensitive HIV-1 after heterosexual transmission.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.06.013

Prospects for an AIDS vaccine: three big questions, no easy answers.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.06.013

Viral dynamics and CD4+ T cell counts in subtype C human immunodeficiency virus type 1-infected individuals from southern Africa

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.06.013

Insensitivity of paediatric HIV-1 subtype C viruses to broadly neutralising monoclonal antibodies raised against subtype B

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.06.013

Neutralizing antibody responses in acute human immunodeficiency virus type 1 subtype C infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.06.013

A Simple, Fast, and Accurate Algorithm to Estimate Large Phylogenies by Maximum Likelihood

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.06.013

Postnatal passive immunization of neonatal macaques with a triple combination of human monoclonal antibodies against oral simian-human immunodeficiency virus challenge

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.06.013

Prospects for vaccine protection against HIV-1 infection and AIDS.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.06.013

Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.06.013

Evidence for potent autologous neutralizing antibody titers and compact envelopes in early infection with subtype C human immunodeficiency virus type 1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.06.013

Genetic and neutralization properties of subtype C human immunodeficiency virus type 1 molecular env clones from acute and early heterosexually acquired infections in Southern Africa

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.06.013

V2 loop glycosylation of the human immunodeficiency virus type 1 SF162 envelope facilitates interaction of this protein with CD4 and CCR5 receptors and protects the virus from neutralization by anti-V3 loop and anti-CD4 binding site antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.06.013

Defining the Protective Antibody Response for HIV-1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.06.013

Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.06.013

GP120: target for neutralizing HIV-1 antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.06.013

Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.06.013

The V1/V2 domain of gp120 is a global regulator of the sensitivity of primary human immunodeficiency virus type 1 isolates to neutralization by antibodies commonly induced upon infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.06.013

Rapid evolution of the neutralizing antibody response to HIV type 1 infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.06.013

Human immunodeficiency virus type 1 V1-V2 envelope loop sequences expand and add glycosylation sites over the course of infection, and these modifications affect antibody neutralization sensitivity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.06.013

Changes in the immunogenic properties of soluble gp140 human immunodeficiency virus envelope constructs upon partial deletion of the second hypervariable region

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.06.013

Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.06.013

Prevention of virus transmission to macaque monkeys by a vaginally applied monoclonal antibody to HIV-1 gp120.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.06.013

Antibody neutralization and escape by HIV-1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.06.013

Characterization and selection of HIV-1 subtype C isolates for use in vaccine development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.06.013

Anti-human immunodeficiency virus type 1 (HIV-1) antibodies 2F5 and 4E10 require surprisingly few crucial residues in the membrane-proximal external region of glycoprotein gp41 to neutralize HIV-1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.06.013

Selection for neutralization resistance of the simian/human immunodeficiency virus SHIVSF33A variant in vivo by virtue of sequence changes in the extracellular envelope glycoprotein that modify N-linked glycosylation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.06.013

inferred from DOI database lookup

7 January 2021

based on heuristic

Protection of Macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.06.013

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.VIROL.2007.06.013

1 reference

25 November 2017

1 reference